PCCA-DT

Across TCGA pan-cancer cohorts, PCCA-DT RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of PCCA-DT’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where PCCA-DT RNA is repressed in tumor relative to normal tissue. In most cancer types PCCA-DT is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

KIRC, BLCA, and LUAD are the cancer types where PCCA-DT tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PCCA-DT RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−1.135	<.001	11	view →
BLCA	All	III,IV	+1.336	<.001	10	view →
LUAD	Female	III,IV	+1.856	<.001	8	view →
KICH	Female	II,III,IV	−1.640	<.001	8	view →
LUSC	Female	All	+2.013	<.001	6	view →
UCEC	All	III,IV	+1.732	<.001	6	view →
CHOL	Male	All	+0.830	.001	4	view →
LIHC	All	All	+0.513	<.001	4	view →
BRCA	Female	All	+0.310	.002	4	view →
THCA	All	All	−0.282	.010	3	view →
PRAD	All	All	+0.588	.004	2	view →
KIRP	Male	All	−0.463	.002	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

PCCA-DT–KIRC

Open the KIRC breakdown →